Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Life sciences company Neogen (NASDAQ:NEOG) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.4% year on year to $221 million. The company’s full-year revenue guidance of $895 million at the midpoint came in 1.7% below analysts’ estimates. Its non-GAAP profit of $0.10 per share was 13% below analysts’ consensus estimates.
Let’s dig into the relative performance of Abbott Laboratories (NYSE:ABT) and its peers as we unravel the now-completed Q4 medical devices & supplies - diversified earnings season.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including CooperCompanies (NASDAQ:COO) and its peers.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSE:SYK).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSE:BAX).
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQ:NEOG) and its peers.
Shareholders of Neogen would probably like to forget the past six months even happened. The stock dropped 36.5% and now trades at $10.42. This might have investors contemplating their next move.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best and worst performers in the medical devices & supplies - diversified industry.
Life sciences company Neogen (NASDAQ:NEOG) beat Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $231.3 million. Its non-GAAP profit of $0.11 per share was in line with analysts’ consensus estimates.
